Literature DB >> 23828202

Liver stiffness increases acutely during sickle cell vaso-occlusive crisis.

Christopher Koh1, Tiffany Turner, Xiongce Zhao, Caterina P Minniti, Jordan J Feld, Jennifer Simpson, Mary Demino, Anna K Conrey, Mary J Jackson, Catherine Seamon, David E Kleiner, Gregory J Kato, Theo Heller.   

Abstract

Acute vaso-occlusive crisis (VOC) in sickle cell disease (SCD) is an important cause of end-organ damage. It is estimated that 10-39% of VOC occurs with hepatic involvement. Current assessments of hepatic involvement during VOC are unsatisfactory. We investigated transient elastography (TE) as a marker of hepatic involvement, its relationship with histology, and biochemical markers during VOC. SCD patients were evaluated with biochemical markers and TE at steady-state and during VOC. Change in TE and biochemical markers were correlated with length of hospital stay. When available, liver biopsy and tricuspid regurgitation velocity (TRV) at steady-state were correlated with TE. Twenty-three patients were evaluated (mean age = 34.3 years, standard deviation = 7.96). In 15 patients with liver biopsies, TE correlated with fibrosis (P = 0.01) and TRV (P = 0.0063), but not hepatic iron. Hemolysis biomarkers changed during VOC (P < 0.022), but not alanine aminotransferase (ALT). Paired comparison of TE at steady-state and during VOC showed an increased from 6.2 to 12.3 kPa (P = 0.0029). Increasing TE during VOC associated with increasing ALT and alkaline phosphatase (P = 0.0088 and 0.0099, respectively). At steady-state, increasing inflammation on biopsy (P = 0.0037) and TRV (P = 0.0075) correlated with increasing TE during VOC. Increased hospital stay was associated with higher ALT (P = 0.041), lower albumin (P = 0.046), hemoglobin/hematocrit (P < 0.0021) but not TE. TE may identify patients with hepatic involvement during VOC independent of biochemical measures. Increase in TE may reflect both hepatic passive congestion and hepatic involvement during VOC. TE may serve as a physiological biomarker for hepatic features of VOC.
Copyright © 2013 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23828202      PMCID: PMC3808506          DOI: 10.1002/ajh.23532

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  48 in total

1.  Nodular regenerative hyperplasia of the liver and focal global glomerulosclerosis associated with sickle cell anemia.

Authors:  Khalid A Al-Mukhaizeem; Esther Lamoureux; Arthur Rosenberg; Averell H Sherker
Journal:  Dig Dis Sci       Date:  2002-02       Impact factor: 3.199

Review 2.  Sickle cell hepatopathy.

Authors:  S Banerjee; C Owen; S Chopra
Journal:  Hepatology       Date:  2001-05       Impact factor: 17.425

3.  Sickle cell hepatopathy.

Authors:  T W Sheehy
Journal:  South Med J       Date:  1977-05       Impact factor: 0.954

4.  Elastography, spleen size, and platelet count identify portal hypertension in patients with compensated cirrhosis.

Authors:  Annalisa Berzigotti; Susana Seijo; Umberto Arena; Juan G Abraldes; Francesco Vizzutti; Juan Carlos García-Pagán; Massimo Pinzani; Jaime Bosch
Journal:  Gastroenterology       Date:  2012-10-08       Impact factor: 22.682

5.  Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C.

Authors:  Laurent Castéra; Julien Vergniol; Juliette Foucher; Brigitte Le Bail; Elise Chanteloup; Maud Haaser; Monique Darriet; Patrice Couzigou; Victor De Lédinghen
Journal:  Gastroenterology       Date:  2005-02       Impact factor: 22.682

6.  Definitions of the phenotypic manifestations of sickle cell disease.

Authors:  Samir K Ballas; Susan Lieff; Lennette J Benjamin; Carlton D Dampier; Matthew M Heeney; Carolyn Hoppe; Cage S Johnson; Zora R Rogers; Kim Smith-Whitley; Winfred C Wang; Marilyn J Telen
Journal:  Am J Hematol       Date:  2010-01       Impact factor: 10.047

7.  Diagnosis of liver fibrosis using FibroScan and other noninvasive methods in patients with hemochromatosis: a prospective study.

Authors:  X Adhoute; J Foucher; D Laharie; E Terrebonne; J Vergniol; L Castéra; B Lovato; E Chanteloup; W Merrouche; P Couzigou; V de Lédinghen
Journal:  Gastroenterol Clin Biol       Date:  2008-02

8.  Hepatic dysfunction in sickle cell disease: a new system of classification based on global assessment.

Authors:  Philip A Berry; Timothy J S Cross; Swee Lay Thein; Bernard C Portmann; Julia A Wendon; John B Karani; Michael A Heneghan; Adrian Bomford
Journal:  Clin Gastroenterol Hepatol       Date:  2007-09-27       Impact factor: 11.382

9.  Acute sickle cell hepatopathy represents a potential contraindication for percutaneous liver biopsy.

Authors:  Nada Zakaria; Alex Knisely; Bernard Portmann; Giorgina Mieli-Vergani; Julia Wendon; Roopen Arya; John Devlin
Journal:  Blood       Date:  2002-08-15       Impact factor: 22.113

Review 10.  Molecular basis of erythrocyte adhesion to endothelial cells in diseases.

Authors:  Jean-Luc Wautier; Marie-Paule Wautier
Journal:  Clin Hemorheol Microcirc       Date:  2013       Impact factor: 2.375

View more
  3 in total

1.  Interim assessment of liver damage in patients with sickle cell disease using new non-invasive techniques.

Authors:  Emma Drasar; Emer Fitzpatrick; Kate Gardner; Moji Awogbade; Anil Dhawan; Adrian Bomford; Abid Suddle; Swee L Thein
Journal:  Br J Haematol       Date:  2016-12-16       Impact factor: 6.998

2.  Vibration Controlled Transient Elastography (Fibroscan®) in sickle cell liver disease - could we strike while the liver is hard?

Authors:  Gil Ben Yakov; Disha Sharma; Hawwa Alao; Pallavi Surana; Devika Kapuria; Ohad Etzion; Matthew M Hsieh; John F Tisdale; Courtney D Fitzhugh; David E Kleiner; Elliot B Levy; Richard Chang; Elenita Rivera; Amy Huang; Christopher Koh; Theo Heller
Journal:  Br J Haematol       Date:  2019-06-19       Impact factor: 8.615

3.  Transient Elastography (TE) is a Useful Tool for Assessing the Response of Liver Iron Chelation in Sickle Cell Disease Patients.

Authors:  Sophia Delicou; Konstantinos Maragkos; Maria Tambaki; Dimitrios Kountouras; John Koskinas
Journal:  Mediterr J Hematol Infect Dis       Date:  2018-09-01       Impact factor: 2.576

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.